ArticleCancer reports (Hoboken, N.J.)2026
Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary neuroendocrine carcinoma of the breast (NECB) represents an exceedingly rare entity, comprising less than 0.5% of all breast carcinomas and approximately 1% of all neuroendocrine neoplasms. The 2019 WHO classification defines NECB as tumors expressing neuroendocrine markers in > 90% of tumor cells with morphological features resembling neuroendocrine tumors of other anatomical sites. CASE PRESENTATION: A 61-year-old postmenopausal female presented with a palpable left breast mass. Clinical examination revealed a 2 × 3 cm firm, poorly circumscribed mass at the 9 o'clock position with multiple satellite lesions and a solitary axillary lymph node measuring 1.5 × 1.5 cm with rubbery consistency. Sonographic evaluation demonstrated a hypoechoic mass with spiculated margins, heterogeneous echotexture, and posterior acoustic shadowing, classified as BI-RADS 6. Core needle biopsy yielded an initial diagnosis of infiltrative ductal carcinoma, grade III, with immunohistochemistry demonstrating ER+/PR+/HER2- status and a Ki-67 index of 22%. Following modified radical mastectomy, comprehensive histopathological examination revealed distinctive neuroendocrine morphology with diffuse positivity for synaptophysin and chromogranin A, confirming the diagnosis of primary neuroendocrine carcinoma of the breast, grade 2, T2N0M0. The patient underwent multimodal therapy comprising modified radical mastectomy with sentinel lymph node biopsy (all 17 nodes negative), adjuvant anthracycline-taxane chemotherapy, chest wall radiation (50 Gy in 25 fractions), and endocrine therapy with anastrozole.
conclusionThis case highlights the diagnostic challenges of NECB, which frequently mimics conventional breast carcinoma on initial assessment. The diagnostic discordance between core biopsy and final pathology underscores the imperative for comprehensive immunohistochemical evaluation in morphologically suggestive cases. Management strategies integrate established breast cancer protocols with neuroendocrine-specific considerations, though optimal treatment paradigms remain incompletely defined due to the paucity of dedicated clinical trials for this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.